FI953756A - Menetelmä lipidivaipattomien virusten inaktivoimiseksi - Google Patents

Menetelmä lipidivaipattomien virusten inaktivoimiseksi Download PDF

Info

Publication number
FI953756A
FI953756A FI953756A FI953756A FI953756A FI 953756 A FI953756 A FI 953756A FI 953756 A FI953756 A FI 953756A FI 953756 A FI953756 A FI 953756A FI 953756 A FI953756 A FI 953756A
Authority
FI
Finland
Prior art keywords
enveloped viruses
lipid enveloped
hours
inactivating non
viruses
Prior art date
Application number
FI953756A
Other languages
English (en)
Swedish (sv)
Other versions
FI953756A0 (fi
Inventor
Monika Stadler
Horst Schwinn
Djuro Josic
Werner Gehringer
Frederic Bal
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25922869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI953756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4318435A external-priority patent/DE4318435C2/de
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of FI953756A0 publication Critical patent/FI953756A0/fi
Publication of FI953756A publication Critical patent/FI953756A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI953756A 1993-02-09 1995-08-08 Menetelmä lipidivaipattomien virusten inaktivoimiseksi FI953756A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4303609 1993-02-09
DE4318435A DE4318435C2 (de) 1993-02-09 1993-06-03 Verfahren zur Inaktivierung von Viren, die nicht mit Lipidhüllen versehen sind
PCT/EP1994/000328 WO1994017834A1 (de) 1993-02-09 1994-02-05 Verfahren zur inaktivierung von viren, die nicht mit lipidhüllen versehen sind

Publications (2)

Publication Number Publication Date
FI953756A0 FI953756A0 (fi) 1995-08-08
FI953756A true FI953756A (fi) 1995-09-12

Family

ID=25922869

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953756A FI953756A (fi) 1993-02-09 1995-08-08 Menetelmä lipidivaipattomien virusten inaktivoimiseksi

Country Status (10)

Country Link
US (1) US6528246B2 (fi)
EP (1) EP0683678B1 (fi)
JP (1) JPH08506498A (fi)
CN (1) CN1064552C (fi)
AT (1) ATE168274T1 (fi)
AU (1) AU676011B2 (fi)
CA (1) CA2155337A1 (fi)
ES (1) ES2118386T3 (fi)
FI (1) FI953756A (fi)
WO (1) WO1994017834A1 (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6034073A (en) * 1995-04-24 2000-03-07 Novavax, Inc. Solvent detergent emulsions having antiviral activity
US6136865A (en) * 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
DE19923027C2 (de) 1999-05-19 2002-09-19 Aventis Behring Gmbh Verfahren zur Inaktivierung von Viren
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
CA2742817A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5118795A (en) 1987-05-15 1992-06-02 University Of Southern California Sequential heat treatment of blood-clotting factor products
DE3730533A1 (de) * 1987-09-11 1989-03-30 Biotest Pharma Gmbh Verfahren zur sterilisation von plasma oder plasmafraktionen
ATE85221T1 (de) * 1988-11-05 1993-02-15 Octapharma Ag Verfahren zur herstellung eines hochreinen, nicht infektioesen antihaemophiliefaktors mittels chromatographie.
JP2926728B2 (ja) * 1988-12-29 1999-07-28 吉富製薬株式会社 蛋白質含有組成物の製造方法
CA2007545A1 (en) * 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
JP3145696B2 (ja) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 分泌型免疫グロブリンａ製剤の製造法
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes

Also Published As

Publication number Publication date
CN1118144A (zh) 1996-03-06
FI953756A0 (fi) 1995-08-08
US20020068355A1 (en) 2002-06-06
AU676011B2 (en) 1997-02-27
CA2155337A1 (en) 1994-08-18
JPH08506498A (ja) 1996-07-16
EP0683678B1 (de) 1998-07-15
CN1064552C (zh) 2001-04-18
EP0683678A1 (de) 1995-11-29
AU6038994A (en) 1994-08-29
WO1994017834A1 (de) 1994-08-18
ATE168274T1 (de) 1998-08-15
US6528246B2 (en) 2003-03-04
ES2118386T3 (es) 1998-09-16

Similar Documents

Publication Publication Date Title
FI960281A0 (fi) Menetelmä tuotteiden sterilisoimiseksi
ES2032316T3 (es) Procedimiento para la esterilizacion de plasma o fracciones de plasma.
FI971610A0 (fi) Menetelmä syklisten depsipeptidien sulfonyloimiseksi, sulfenyloimiseksi, ja fosforyloimiseksi
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DK1019368T3 (da) Acylsulfamoylbenzoesyreamider, nytteplantebeskyttelsesmidler indeholdende disse samt fremgangsmåder til deres fremstilling
HK1041521A1 (en) Growth differentiation factor inhibitors and uses therefor
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
FI953756A (fi) Menetelmä lipidivaipattomien virusten inaktivoimiseksi
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DE59103664D1 (de) Verfahren zur Inhibierung und Zerstörung von Peroxiden in Dialkylethern.
AR003639A1 (es) Mezclas herbicidas sinergicas que contienen eteres de oxima de ciclohexenona, composiciones herbicidas formuladas con dichas mezclas, procedimiento para preparar dichas composiciones y metodo para combatir el crecimiento de plantas indeseables
ATE292382T1 (de) Zur inaktivierung von infektiösen proteinen behandelte zusammensetzungen
ATE253368T1 (de) Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
ES2057638T3 (es) Composiciones insecticidas a base de bacillus thuringiensis.
NO951989D0 (no) Anvendelse av amidoaminer i öyepreparater
DE59707067D1 (de) Verfahren zur inaktivierung von lipidumhüllten viren mit lipopeptiden und neue antivirale lipopeptide
ATE306929T1 (de) Inositolphosphoglycan und ribose zur behandlung von ischämischen-reperfusionschaden
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
PT703916E (pt) Marcfortinas substituidas em 14 e derivados uteis como agentes antiparasiticos
ATE113843T1 (de) Verwendung eines prolylendopeptidase-inhibitors zur behandlung von aids.
NZ323207A (en) Hemoregulatory compounds